文献速递神经免疫

多发性硬化疾病修正治疗临床试验中的结局报告偏倚

Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis.
PubMed 文献 · Neurology · 2024-02-26

该研究检索ClinicalTrials.gov中2007年9月后注册、2018年底前完成的多发性硬化免疫调节药物临床试验,共535项符合条件,其中101项有匹配发表。95%的试验存在注册与发表的原发或次要结局不一致,44%的发表次要结局未在注册中列出,仅三分之二试验在开始前注册。作者认为选择性结局报告在多发性硬化疾病修正药物试验中普遍存在。

要点

  • 95%的试验注册与发表的原发或次要结局存在不一致。
  • 44%的发表次要结局未包含在注册记录中。
  • 仅三分之二试验在开始日期前注册,62%试验在试验期间或之后修改了注册结局。

核心结论

  • 选择性结局报告在多发性硬化疾病修正药物试验中普遍存在,作者提出减少该偏倚的方法。

研究设计与样本

  • 研究检索ClinicalTrials.gov中2007年9月后注册、2018年底前完成的多发性硬化免疫调节药物疗效与安全性临床试验,共535项符合条件,其中101项有匹配发表。

主要发现

  • 95%的试验存在注册与发表的原发或次要结局不一致,包括26篇发表中注册与发表的原发结局不一致。
  • 44%的发表次要结局未包含在注册记录中。
  • 注册与非注册报告的原发疗效结局为阳性的比例相似。
  • 非企业资助和开放标签的多发性硬化试验更易出现选择性原发结局报告,但未达统计学显著。
  • 仅三分之二试验在开始日期前注册于ClinicalTrials.gov,62%的试验在试验期间或之后对注册结局进行了修改。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Outcome reporting bias occurs when publication of trial results is dependent on clinical significance, thereby threatening the validity of trial results. Research on immunomodulatory drugs in multiple sclerosis has thrived in recent years. We aim to comprehensively examine to what extent outcome reporting bias is present in these trials and the possible underlying factors. METHODS: We identified clinical trials evaluating the efficacy and safety of immunomodulatory drugs in patients with multiple sclerosis (MS) registered in ClinicalTrials.gov after September 2007 and completed before the end of 2018. Information about study design, type of funding, and primary and secondary outcome measures was extracted from the registry. Timing of registration in relation to study initiation and subsequent amendments to the planned outcomes were reviewed. Publications related to these trials were identified in several bibliographic databases using the trial registration number. Registered primary and secondary outcomes were recorded for each trial and compared with outcomes in the publication describing the main outcomes of the trial. RESULTS: A search of ClinicalTrials.gov identified 535 eligible registered clinical trials; of these, 101 had a matching publication. Discrepancies between registered and published primary and secondary outcomes were found in 95% of the trials, including discrepancies between the registered and published primary outcomes in 26 publications. Forty-four percent of the published secondary outcomes were not included in the registry. A similar proportion of registered and nonregistered reported primary efficacy outcomes were positive (favoring the intervention). Nonindustry-funded and open-label trials in MS were more prone to selective primary outcome reporting, although these findings did not reach statistical significance. Only two-thirds of the trials were registered in ClinicalTrials.gov before the trial start date, and 62% of trials made amendments in registered outcomes during or after the trial period. DISCUSSION: Selective outcome reporting is prevalent in trials of disease-modifying drugs in people with MS. We propose methods to diminish the occurrence of this bias in future research.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lemmens CMC, van Amerongen S, Strijbis EM, et al. Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis. Neurology. 2024. PMID: 38408286. doi:10.1212/WNL.0000000000208032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。